Cargando…
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231931/ https://www.ncbi.nlm.nih.gov/pubmed/34199189 http://dx.doi.org/10.3390/nu13062031 |
_version_ | 1783713528663769088 |
---|---|
author | Gallelli, Giuseppe Di Mizio, Giulio Palleria, Caterina Siniscalchi, Antonio Rubino, Paolo Muraca, Lucia Cione, Erika Salerno, Monica De Sarro, Giovambattista Gallelli, Luca |
author_facet | Gallelli, Giuseppe Di Mizio, Giulio Palleria, Caterina Siniscalchi, Antonio Rubino, Paolo Muraca, Lucia Cione, Erika Salerno, Monica De Sarro, Giovambattista Gallelli, Luca |
author_sort | Gallelli, Giuseppe |
collection | PubMed |
description | Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases. |
format | Online Article Text |
id | pubmed-8231931 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82319312021-06-26 Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases Gallelli, Giuseppe Di Mizio, Giulio Palleria, Caterina Siniscalchi, Antonio Rubino, Paolo Muraca, Lucia Cione, Erika Salerno, Monica De Sarro, Giovambattista Gallelli, Luca Nutrients Article Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases. MDPI 2021-06-13 /pmc/articles/PMC8231931/ /pubmed/34199189 http://dx.doi.org/10.3390/nu13062031 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gallelli, Giuseppe Di Mizio, Giulio Palleria, Caterina Siniscalchi, Antonio Rubino, Paolo Muraca, Lucia Cione, Erika Salerno, Monica De Sarro, Giovambattista Gallelli, Luca Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title_full | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title_fullStr | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title_full_unstemmed | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title_short | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases |
title_sort | data recorded in real life support the safety of nattokinase in patients with vascular diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231931/ https://www.ncbi.nlm.nih.gov/pubmed/34199189 http://dx.doi.org/10.3390/nu13062031 |
work_keys_str_mv | AT gallelligiuseppe datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT dimiziogiulio datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT palleriacaterina datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT siniscalchiantonio datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT rubinopaolo datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT muracalucia datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT cioneerika datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT salernomonica datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT desarrogiovambattista datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases AT gallelliluca datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases |